One of the first trials to demonstrate the potential combination ICI therapy for HCC was a trial that treated 148 patients with HCC who had previously been on sorafenib to receive nivolumab and/or ipilimumab (CTLA-4 inhibitor) at different doses and intervals [26]. This evidence concerns the gene CTLA4 and hepatocellular carcinoma.